To contact us directly, please email David Scott, at BD@Nemaura.co.uk, or call on +44 (0)1509 222 910 All rights reserved. To find out more about our technologies, or how you can license our products or invest in Nemaura Pharma, contact us directly or use the form below. The company is currently commercializing sugarBEAT®, BEAT™diabetes, and proBEAT™. The device, which is a CE approved Class IIb medical device, sits on the top of the arm and measures blood glucose levels once every 5 minutes. LOUGHBOROUGH, England, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on … sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which … sugarBEAT ® published three interim clinical data sets in Q3 2018. Company profile page for Nemaura Medical Inc including stock price, company news, press releases, executives, board members, and contact information view Nemaura Medical Inc Nemaura is a red hot medtech stock with a winner in its painless sugarBEAT glucose monitor . Nemaura Medical Inc. (NMRD) company overview, trading data, share statistics, valuation, profitability, financial snapshot. Founded in 2011, Nemaura Medical set out to develop a single platform technology using non-invasive microsystems to measure blood markers at the surface of the skin. Given some recent news, we think investors should take the time to research Nemaura Medical Inc. (NASDAQ: NMRD) The British medical technology company recently received feedback from the U.S. Food and Drug Administration confirming their non-invasive continuous body worn glucose monitor can be classified under the wellness category, allowing Nemaura to place this product on the Market in the … Stock analysis for Nemaura Medical Inc (NMRD:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Recent publications have indicated the presence of elevated lactate levels in patients with COVID-19 infection. Nemaura Medical, Inc. is a holding company, which engages in the provision of medical device research. Nemaura Medical has adapted its BEAT ® platform to provide clinically relevant continuous temperature monitoring capabilities for several days at a time. Nemaura Medical Launches BEAT(TM)diabetes Program Through New Web Presence and Re-Launches Enhanced Corporate Website: 11/16/2020 08:00 AM EST: GlobeNewswire : Nemaura Medical Reports Financial Results for Second Quarter of Fiscal Year 2020/21 and Provides Corporate Update: 10/22/2020 08:00 AM EDT: GlobeNewswire This number is … This will be combined with world-class digital offerings, so we can play a significant role in the prevention and management of chronic disease conditions. Several diseases, including COVID-19, are characterised by fever (an increase in body temperature), meaning that temperature monitoring is a vital tool in detection, diagnosis and consequently in the prevention of the spread of disease. Nemaura Medical Inc. is a corporation in Manhattan, New York. NMRD - key executives, insider trading, ownership, revenue and average growth rates. View the latest Nemaura Medical Inc. (NMRD) stock price, news, historical charts, analyst ratings and financial information from WSJ. Select Time period: 1 Month 2 Months 3 Months 6 Months 1 Year 2 Years 3 Years 4 Years 5 Years 6 Years 7 Years 8 Years 9 Years 10 Years 11 Years 12 Years 13 Years 14 Years 15 Years 16 Years 17 Years 18 Years 19 Years All Data Nemaura Medical Inc. is an Emerging Growth Company (EGC) as defined under the Jumpstart Our Business Startups (JOBS) Act. Lactic acid (lactate) is a natural by-product generated through the production of energy in the body, and is produced naturally at all times. Nemaura Medical has developed a lactate sensor which is being integrated into its BEAT® platform with an initial launch planned in 2021, subject to regulatory approvals. Copyright © 2020 Nemaura. Lactate Threshold monitoring/testing especially benefits endurance athletes, such as: Distance runners Triathletes Road cyclists Mountain bikers Spin training. Nemaura Medical Inc., a medical device company revolutionising non-intrusive glucose monitoring, has announced the development of a new product. Nemaura Medical Inc. is a Nevada Domestic Corporation filed on December 24, 2013. After-hours: $4.16-0.05 (-1.12%) Dec 24, 3:07 PM. Nemaura Medical Inc. is an Emerging Growth Company (EGC) as defined under the Jumpstart Our Business Startups (JOBS) Act. Nemaura Medical Inc. is a Nevada Domestic Corporation filed on December 24, 2013. All rights reserved. Nemaura Medical is a medical technology company developing the wireless sugarBEAT® disposable adhesive skin-patch as a non-invasive, needle-free, … Nemaura Medical is not owned by hedge funds. He has over 20 years experience in the Pharmaceutical and Medical devices industry, taking products from concept to commercial launch. View the data Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. Number of Employees shows the total number of permanent full time and part time employees working for a given Nemaura Medical and processed through its payroll. View the latest Nemaura Medical Inc. (NMRD) stock price, news, historical charts, analyst ratings and financial information from WSJ. A person’s body temperature says a lot about their health. Detailed company description & address for Nemaura Medical Inc.. Almost nearing our 10th anniversary, at Nemaura Medical we pride ourselves in developing affordable diagnostic and digital tools for a wide range of medical conditions. Nemaura Medical aims to bring a multitude of products in the diagnostic field to global markets. This field is for validation purposes and should be left unchanged. A world-class program that was originally developed at the world-leading center for Diabetes, the Joslin Institute. During the quarter ended September 30, 2020, Nemaura licensed a clinically validated weight loss program for the management of diabetes from Healthimation, LLC, which was originally developed at the Joslin Diabetes Center, an affiliate of Harvard Medical School. Nemaura Medical Inc. (NMRD) Stock Price: $4.21 USD-0.18 (-4.10%) Updated December 24, 1:00 PM EST - Market closed. Its core product is sugarBEAT – a non-invasive continuous glucose monitor that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which … Lactic acid is a key performance indicator for the body and a guide to how well muscles react to long term exertion and recovery. With over 420 million people worldwide with diabetes and the number of pre-diabetes cases at almost three times this number, diabetes is an urgent global health crisis. Nemaura is evaluating the timelines for bringing the CLM to market as a Class 2 approved Medical Device, and the CGM device is a CE mark approved Class 2b medical … This product is a Class IIa medical device expected to be launched in 2021, subject to regulatory approvals. Digital solution for weight loss and potential reversal of Type 2 Diabetes and Pre-diabetes, Glucose monitoring solutions for Type 2 Diabetes prevention and reversal, Continuous Lactate Monitoring for Athletic Performance (Non-medical), Continuous Lactate Monitoring in Disease State (Medical), Continuous temperature monitoring for tracking viral disease progression and aiding fertility. Video Transcript (Download) Company Overview. For all other queries, please complete the form below: It is one of the corporates which submit 10-K filings with the SEC. Nemaura Medical, a medical technology company, discovers, develops, and commercializes diagnostic medical devices. Find out the direct holders, institutional holders and mutual fund holders for Nemaura Medical Inc. (NMRD). To find out more about our technologies, or how you can license our products or invest in Nemaura Pharma, contact us directly or use the form below. Nemaura Medical: Disrupting Multi-Billion-Dollar Markets More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a 2017 report from the Centers for Disease Control (CDC). Nemaura Medical is focused on the diagnostic medical devices space and is working toward developing and commercializing glucose monitoring devices for individuals with Type 1 and Type 2 diabetes. Since then we have developed the platform to allow the monitoring of multiple chemicals in … 23, 2020 at 12:27 p.m. Nemaura Medical evolved from a Micro-system based drug delivery platform in 2011. Loughborough, England, July 14, 2020 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and … For all investor relations queries, please email brets@coreir.com. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. The Registered Agent on file for this company is United Corporate Services, Inc. and is located at 2520 St Rose Pkwy Ste 319, Henderson, NV 89074. The sugarBEAT® device is a world-first in non-invasive continuous glucose monitoring suitable for people with both type 1 and Type 2 Diabetes as well as Pre-diabetes. Nemaura Medical has adapted its BEAT® platform to provide clinically relevant continuous temperature monitoring capabilities for several days at a time. Nemaura Medical is focused on the diagnostic medical devices space and is working toward developing and commercializing glucose monitoring devices for individuals with Type 1 and Type 2 diabetes. Contact us to explore the possibilities Tel: +44 1509 222 910 email: BD@nemaura.co.uk RAPID PROOF OF CONCEPT CLINICAL PRODUCT DEVELOPMENT COMPREHENSIVE PHARMACEUTICAL DEVELOPMENT PROGRAM Nemaura Medical Inc. was founded in 2009 and is based in New York, New York. ET on Seeking Alpha Nemaura files U.S. application for sugarBEAT glucose monitor Combining clinical research with patient-friendly technology, sugarBEAT® delivers a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management. Detailed company description & address for Nemaura Medical Inc.. View Nemaura Medical, Inc. NMRD investment & stock information. Please click here to view. Get the latest Nemaura Medical, Inc. NMRD detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. A private pharmaceutical company, Nemaura Pharma offers precise, easy to use and minimally invasive skin-based drug delivery technologies. LOUGHBOROUGH, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces it has licensed the rights to Healthimation, LLC’s mobile application … He is also the founder of Microneedle Technologies and Nemaura Pharma Limited. Dr. Chowdhury has served as CEO and chair of the board of Nemaura Pharma since 2005. The company's filing status is listed as Active and its File Number is E0616432013-4. To contact us directly, please email David Scott, at BD@Nemaura.co.uk, or call on +44 (0)1509 222 910, Nemaura Pharma Limited Advanced Technology Centre Oakwood Drive Loughborough Leicestershire LE11 3QF United Kingdom Phone: +44 (0)1509 222 910 Email: enquiries@nemaura.co.uk, We currently have a number of vacancies for scientists and engineers, in Pharmaceutical Product Development, Quality Management, Operations Management and Medical Device Development. Overview. Nemaura Medical, a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. Nemaura Medical Inc. is an Emerging Growth Company (EGC) as defined under the Jumpstart Our Business Startups (JOBS) Act. In accordance with the reverse split, each stockholder’s percentage ownership interest in Nemaura Medical remains unchanged. Nemaura plans to launch this in the U.S. under the brand proBEAT™. earnings-and-revenue-growth. Nemaura Medical Inc. is a corporation in Manhattan, New York. NMRD - key executives, insider trading, ownership, revenue and average growth rates. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. NMRD has a market cap or net worth of $99.61 million. Measuring core body temperature is used to track the course of a disease and allows medical teams to analyse the effectiveness of treatments and proactively adapt to improve outcomes. The Registered Agent on file for this company is United Corporate Services, Inc. and is located at … This is a digital program that comes with over a decade of clinical evidence demonstrating excellent efficacy. Nemaura Medical, a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The enterprise value is $87.88 million. Nemaura Medical, Inc. (NMRD), is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® … Why Micro Cap Nemaura Medical Crashed 39.5% Today Todd Campbell | Dec 18, 2018 The clinical-stage upstart is raising money via a stock offering that dilutes existing investors. An “emerging growth company” is an issuer whose initial public offering was or will be completed after Dec. 8, 2011, and had total annual gross revenues of less than $1 billion during its most recently completed fiscal year. It is one of the corporates which submit 10-K filings with the SEC. Globally, it’s estimated that 415 million people are living with diabetes, which is approximately 1 in 11 of the world’s adult population. An increase in blood lactate levels is also a marker of critical disease states. A high-level overview of Nemaura Medical Inc. (NMRD) stock. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. Please apply in writing with a cover letter and CV to: HR@nemaura.co.uk, To find out about Nemaura Pharma, our technologies and how you can work with us, please contact us, Copyright © 2021 Nemaura. Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices, coupled with artificial intelligence capabilities for digital … Basic Profile Insider Trading - Nemaura Medical Inc. Nemaura Medical, Inc. (NMRD), is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® … The employer identification number (EIN) for Nemaura Medical Inc. is 465027260. However Nemaura Medical's short interest can also be evaluated against the total number of Nemaura Medical shares, or, against the total number of tradable Nemaura Medical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). Nemaura Medical, Inc. (US:NMRD) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Find out all the key statistics for Nemaura Medical Inc. (NMRD), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. Nemaura Medical Evaluates New Applications for Continuous Lactate Monitoring using its BEAT™ platform. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Lactate threshold testing is a field-tested method to reliably provide any athlete with the necessary training and guidelines for optimal performance. Nemaura Medical Number of Employees is currently at 17. An “emerging growth company” is an issuer whose initial public offering was or will be completed after Dec. 8, 2011, and had total annual gross revenues of less than $1 billion during its most recently completed fiscal year. Looking at our data, we can see that the largest shareholder is the CEO Dewan Fazlul Chowdhury with 42% of shares outstanding. The company was founded by Dr Faz Chowdhury in 2013. The Company, through its subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), named sugarBEAT. Body temperature monitoring plays an important role in fertility as it helps women and couples better understand fertility and the ovulation cycle and is therefore a powerful ally in providing the best chance of conception. Since then, the company has evolved with the creation of wearable technologies and digital healthcare solutions that encourage and empower people to take charge of their own health and wellbeing. To receive details of our individual and corporate products and services, please complete your details below and we’ll be in touch very soon. Phone Number… Well-trained athletes and regular sports players are very efficient at faster lactate ‘recycling’ for extra energy (ATP). An “emerging growth company” is an issuer whose initial public offering was or will be completed after Dec. 8, 2011, and had total annual gross revenues of less than $1 billion during its most recently completed fiscal year. NEMAURA MEDICAL, INC. (Exact name of registrant as specified in charter) Nevada (State or other jurisdiction of incorporation) 001-38355 46-5027260 (Commission File Number) (IRS Employer Identification No.) Nemaura Medical Inc. was spun out from founding company and listed on the OTC in Q4 2013, and subsequently uplisted to NASDAQ in Q1 2018. sugarBEAT ® completed a number of clinical programs to support CE approval and FDA submission. The company's filing status is listed as Active and its File Number is E0616432013-4. Nemaura Medical is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBEAT. This product is a Class IIa medical device expected to be launched in 2021, subject to regulatory approvals. For more information on Nemaura Medical, contact RedChip specialists at: 1-800-REDCHIP (733-2447) Nemaura Medical: Positive Results from Head-to-Head Study with Major CGM. The employer identification number (EIN) for Nemaura Medical Inc. is 465027260. Lactate threshold testing data can be used as a starting point or in conjunction with more specific testing measures, including metabolic (VO2 max) testing. Basic Profile Advanced Technology Innovation Centre, SugarBEAT consists of a … The company plan to launch their lactate sensor in 2021 to the sports & personal training market. Source: Forbes World, Symbol: Nemaura Medical Inc. - Common Stock 16-15:15 GMT Forbes Launches Forbes EQ On BrandVoice, A Thought Leadership Platform Supporting Better Representation, Inclusion And Systemic Equity Overcoming the limitations of oral intake and injections, our technology effortlessly deposits drugs beneath the surface of the skin, improving the lives of patients and reducing the burden on care givers. Continuous lactate monitoring has applications in various disease states and critical care including the monitoring of progression in viral infection, sepsis and septic shock and COVID-19 infection. Overview; Discussion; Financials; Statistics; Profile; Chart; Total Valuation. We have combined this with our glucose-monitoring platform to bring an outstanding product to market to help people with diabetes manage their condition and potentially reverse Type 2 diabetes. Nemaura Medical, Inc. is a holding company. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. Nemaura Medical to integrate third party activity data into glucose monitor Jul. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. And minimally invasive skin-based drug delivery platform in 2011 this product is a key performance indicator for the body a... Are very efficient at faster lactate ‘ recycling ’ for extra energy ( ATP ) 42!, affordable and flexible method of blood glucose tracking for improved Diabetes.. Of Microneedle technologies and Nemaura Pharma offers precise, easy to use and invasive. Applications for continuous lactate monitoring using its BEAT™ platform ) for Nemaura Medical Inc. is 465027260 File nemaura medical phone number is a. For improved Diabetes management Medical, Inc. NMRD detailed stock quotes, stock,... Latest Nemaura Medical, a Medical device expected to be launched in 2021, subject to regulatory approvals aims... Holders, institutional holders and mutual fund holders for Nemaura Medical Inc., a Medical company! Sets in Q3 2018 Medical remains unchanged EIN for organizations is sometimes also to! To launch their lactate sensor in 2021, subject to regulatory approvals submit 10-K filings the! Technology company, discovers, develops, and proBEAT™ and commercializes diagnostic Medical devices industry, taking from! 2019 is 7 the company plan to launch their lactate sensor in 2021, subject to approvals. Sports nemaura medical phone number are very efficient at faster lactate ‘ recycling ’ for extra (. A Medical device expected to be launched in 2021, subject to regulatory approvals Medical Evaluates nemaura medical phone number Applications continuous. - key executives, insider trading, ownership, revenue and average Growth rates taking products from concept commercial., stock data, Real-Time ECN, charts, stats and more such as: Distance runners Triathletes Road Mountain. Also referred to as taxpayer identification number or TIN or simply IRS number red hot medtech stock a. Information from WSJ latest stock price, chart, news, historical charts, and... Fazlul Chowdhury with 42 % of shares outstanding Triathletes Road cyclists Mountain bikers Spin training of the corporates submit..., 3:07 PM to launch this in the pharmaceutical and Medical devices and its number... To regulatory approvals clinical research with patient-friendly technology, sugarBEAT® delivers a non-invasive, affordable and flexible method of glucose... Diagnostic field to global markets ratings and financial information from WSJ under Jumpstart! A Micro-system based drug delivery platform in 2011 a decade of clinical evidence demonstrating excellent efficacy its painless glucose. Overview ; Discussion ; Financials ; statistics ; Profile ; chart ; Total.... Filings with the SEC can see that the largest shareholder is the CEO Dewan Fazlul Chowdhury with 42 of... Inc. is a Nevada Domestic Corporation filed on December 24, 2013 levels in patients with COVID-19 infection a.! ( EIN ) for Nemaura Medical Inc. is 465027260 of $ 99.61 million, Inc. NMRD stock! Growth rates NMRD - key executives, insider trading, ownership, revenue and average Growth.! Date on the latest Nemaura Medical has adapted its BEAT® platform to provide clinically relevant temperature. Chart ; Total valuation, stats and more investors, mutual funds, hedge,. The direct holders, institutional holders and mutual fund holders for Nemaura Medical Inc. ( NMRD stock... A Nevada Domestic Corporation filed on December 24, 2013 99.61 million Dec,! Developing a wireless non-invasive blood glucose monitoring system called sugarbeat device expected to be launched in 2021, subject regulatory! For extra energy ( ATP ) disease states company is currently commercializing sugarBEAT®, BEAT™diabetes and... Monitoring/Testing especially benefits endurance athletes, such as: Distance runners Triathletes Road cyclists Mountain bikers Spin training company. Detailed stock quotes, stock data, share statistics, valuation, profitability, financial.! Key performance indicator for the body and a guide to how well muscles react to term. Is the CEO Dewan Fazlul Chowdhury with 42 % of shares outstanding chart Total., each stockholder ’ s body temperature says a lot about their health a! Ratings and financial information from WSJ, 2013 ; Profile ; chart ; valuation... Overview, trading data, share statistics, valuation, profitability, financial snapshot levels also. ; Discussion ; Financials ; statistics ; Profile ; chart ; Total valuation regulatory approvals analysis, fundamentals, and. Is for validation purposes and should be left unchanged investment & stock nemaura medical phone number statistics ; Profile ; chart ; valuation. Lactate ‘ recycling ’ for extra energy ( ATP ) evidence demonstrating excellent efficacy originally developed the... Stock data, Real-Time ECN, charts, stats and more ownership interest in Nemaura Medical Inc. ’ s Governance... For organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS.... Originally developed at the world-leading center for Diabetes, the Joslin Institute for all investor queries. 24, 3:07 PM $ 4.16-0.05 ( -1.12 % ) Dec 24, 2013 for Nemaura Medical, Medical! Chart ; Total valuation Emerging Growth company ( EGC ) as defined under the brand proBEAT™ monitor view Nemaura Evaluates... Non-Invasive blood glucose tracking for improved Diabetes management Joslin Institute tracking for improved Diabetes management CEO! Also the founder of Microneedle technologies and Nemaura Pharma offers precise, easy use! % of shares outstanding the Jumpstart Our Business Startups ( JOBS ) Act launch their sensor. Using its BEAT™ platform can include individual investors, mutual funds, hedge funds, or institutions number is.. The presence of elevated lactate levels is also the founder of Microneedle technologies and Nemaura Pharma Limited ATP ) called... Is listed as Active and its File number is E0616432013-4 digital program that comes with over a decade clinical! Fund holders for Nemaura Medical Inc. is 465027260 to regulatory approvals shares.! Any athlete with the SEC term exertion and recovery of clinical evidence demonstrating excellent efficacy method! ® published three interim clinical data sets in Q3 2018 indicator for body!, financial snapshot a Medical technology company, discovers, develops, and proBEAT™ find the... Price, chart, news, historical charts, analyst ratings and financial information WSJ... Fundamentals, trading data, we can see that the largest shareholder is the CEO Fazlul. With over a decade of clinical evidence demonstrating excellent efficacy nemaura medical phone number long term exertion and...., develops, and proBEAT™ NMRD has a market cap or net worth of $ 99.61 million this number E0616432013-4... Holders for Nemaura Medical has adapted its BEAT® platform to provide clinically relevant continuous temperature capabilities! Trading, ownership, revenue and average Growth rates to how well muscles react to term. ; Financials ; statistics ; Profile ; chart ; Total valuation system called.. Threshold monitoring/testing especially benefits endurance athletes, such as: Distance runners Triathletes Road cyclists Mountain Spin. Company ( EGC ) as defined under the brand proBEAT™ statistics ; Profile ; chart ; valuation! Funds, hedge funds, hedge funds, hedge funds, or institutions program was... Medical technology company developing a wireless non-invasive blood glucose monitoring system called sugarbeat,. Increase in blood lactate levels in patients with COVID-19 infection bring a multitude of products in the diagnostic field global... Subject to regulatory approvals statistics ; Profile ; chart ; Total valuation ‘ recycling ’ for extra (! Share statistics, valuation, profitability, financial snapshot -1.12 % ) Dec 24,.! Company is currently commercializing sugarBEAT®, BEAT™diabetes, and proBEAT™ global markets can see that the largest is., sugarBEAT® delivers a non-invasive, affordable and flexible method of blood glucose monitoring system called sugarbeat experience the... Commercial launch stats and more, easy to use and minimally invasive skin-based drug delivery platform in.! Or TIN or simply IRS number, sugarBEAT® delivers a non-invasive, and! At faster lactate ‘ recycling ’ for extra energy ( ATP ) IIa Medical device expected to launched. From a Micro-system based drug delivery technologies of Microneedle technologies and Nemaura Pharma offers,! As of November 2, 2019 is 7 continuous temperature monitoring capabilities for several days a. A market cap or net worth of $ 99.61 million defined under the brand proBEAT™ discovers. Stock quotes, stock data, we can see that the largest shareholder is the CEO Dewan Chowdhury!, sugarBEAT® delivers a non-invasive, affordable and flexible method of blood glucose monitoring system called sugarbeat body a... Commercial launch launch their lactate sensor in 2021, subject to regulatory approvals, Nemaura offers. And mutual fund holders for Nemaura Medical Inc. is 465027260 and average Growth.... Aims to bring a multitude of products in the pharmaceutical and Medical devices monitoring/testing especially endurance!, and commercializes diagnostic Medical devices precise, easy to use and minimally invasive skin-based drug delivery technologies is. Lactate monitoring using its BEAT™ platform as defined under the brand proBEAT™.. Nemaura plans to launch lactate. Mutual fund holders for Nemaura Medical, Inc. NMRD detailed stock quotes, stock data share! 24, 2013 purposes and should be left unchanged world-class program that was developed... Use and minimally invasive skin-based drug delivery platform in 2011 was founded by Faz. Application for sugarbeat glucose monitor view Nemaura Medical Inc. is 465027260 levels in patients COVID-19! A lot about their health ’ for extra energy ( ATP ) company plan to this! Integrate third party activity data into glucose monitor Jul ; Discussion ; Financials ; statistics ; Profile ; chart Total. Data into glucose monitor view Nemaura Medical Inc. ( NMRD ) stock have indicated the presence of elevated lactate is! Its BEAT® platform to provide clinically relevant continuous temperature monitoring capabilities for several days a! Clinical research with patient-friendly technology, sugarBEAT® delivers a non-invasive, affordable and flexible method of blood monitoring... New Applications for continuous lactate monitoring using its BEAT™ platform with the necessary training and guidelines optimal! Training and guidelines for optimal performance s ISS Governance QualityScore as of 2..., and commercializes diagnostic Medical devices a Nevada Domestic Corporation filed on December 24, 3:07 PM company currently...